Buprenorphine: Partial Mu Agonism, Opioid Use Disorder Treatment and Pain Safety

Reviewed 10 November 2026 for medical education. This is not an individualized prescribing guide; refer to current local product labels and qualified clinicians.

Overview

Buprenorphine is a semisynthetic thebaine-derived opioid with high-affinity, partial agonist action at mu-opioid receptors and antagonist activity at kappa receptors. Depending on formulation and labeling, it treats opioid use disorder (OUD) or selected pain conditions. Importantly, pain formulations and OUD formulations are not automatically interchangeable in dose, delivery or approved indications [1–3].

Receptor pharmacology

Partial mu agonism can produce substantial analgesia and suppression of opioid withdrawal/craving while showing a ceiling for some respiratory effects in controlled settings. However, dangerous respiratory depression can still occur, especially with benzodiazepines, alcohol, other sedatives, lung disease or overdose. High receptor affinity and slow dissociation explain its prolonged activity and the possibility of precipitated withdrawal when it displaces a full opioid agonist before sufficient withdrawal has developed [1,2].

Evidence for opioid use disorder treatment

Buprenorphine is a first-line OUD medication associated with markedly improved retention and lower overdose mortality when continued appropriately. Sublingual buprenorphine or buprenorphine–naloxone and certain extended-release injectable products are examples; formulation-specific initiation and maintenance protocols vary. Discontinuing an opioid agonist without continued support increases recurrence and overdose risks. Therapy should be accessible with counselling and harm-reduction support, and not withheld solely because another necessary medicine has sedating effects [2,3].

Initiation, precipitated withdrawal and naloxone combination

Traditional initiation generally begins once opioid withdrawal is evident, with protocols adjusted for the prior opioid, including fentanyl exposure; supervised low-dose overlapping initiation may be considered in some settings. Buprenorphine–naloxone combinations include naloxone primarily to discourage parenteral misuse, not because the swallowed/sublingual naloxone is the principal OUD treatment. The timing and route must follow current local protocols and the precise product [1,2].

Pharmacokinetics and interactions

Buprenorphine has extensive first-pass metabolism if swallowed, so sublingual/buccal or other formulations are used for systemic exposure. CYP3A4-mediated N-dealkylation to norbuprenorphine and glucuronidation contribute to metabolism; elimination is mainly through bile/feces with variable renal excretion. Strong CYP3A4 inhibitors/inducers can change concentrations, as can severe liver impairment [1].

Safety and special populations

Adverse effects include constipation, sedation, nausea, dizziness, sweating, and occasional QT concerns with specific formulations. Accidental pediatric exposure can be fatal. In pregnancy, buprenorphine is an evidence-based treatment for OUD, with newborn monitoring for treatable neonatal opioid withdrawal. Strong sedatives increase overdose risk, but guidance advises managing these combinations carefully rather than automatically denying OUD treatment. Discuss take-home naloxone and safe storage [2,3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. US Food and Drug Administration. SUBOXONE (buprenorphine and naloxone) sublingual film: US prescribing information. 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022410s057lbl.pdf
  3. Centers for Disease Control and Prevention. Opioid use disorder: treating. 2024. Available from: https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *